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Pharmacological treatment of cognitive 
deficits in nondementing mental health 
disorders
Trevor W. Robbins, PhD
Evidence for pharmacological remediation of cognitive deficits in three major psychiatric disorders—attention deficit- 
hyperactivity disorder (ADHD), schizophrenia, and depression—is reviewed. ADHD is effectively treated with the 
stimulant medications methylphenidate and d-amphetamine, as well as nonstimulants such as atomoxetine, implicating 
cognitive enhancing effects mediated by noradrenaline and dopamine. However, the precise mechanisms underlying 
these effects remains unclear. Cognitive deficits in schizophrenia are less effectively treated, but attempts via a variety 
of neurotransmitter strategies are surveyed. The possibility of treating cognitive deficits in depression via antidepressant 
medication (eg, selective serotonin reuptake inhibitors) and by adjunctive drug treatment has only recently received 
attention because of confounding, or possibly interactive, effects on mood. Prospects for future advances in this important 
area may need to take into account transdiagnostic perspectives on cognition (including neurodegenerative diseases) as well 
as improvements in neuropsychological, neurobiological, and clinical trial design approaches to cognitive enhancement.
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Introduction
This important topic can be considered with either a narrow 
or broad focus. If, for example, the position is taken that most 
psychiatric symptoms can be understood as impairments of 
cognition, or of cognition interacting with emotional or moti-
vational factors (ie, so-called “hot” cognition), then we would 
be discussing the whole remit of pharmacological treatment 
in psychiatry. If on the other hand, we consider specifically 
the deficits in “cold” cognition, for example, memory and 
attention, that accompany such diagnoses as schizophrenia 
and depression and most other neuropsychiatric disorders, 
then we are dealing with a much narrower spectrum. Whilst 
it is now acknowledged that cognitive dysfunctions play a 
major role in mental health disorders, and that describing 
these and their neural basis, and identifying possible pharma-
cological treatments for them, have been important research 
objectives, it must also be admitted that there have been rather 
few clinical successes to date. 
The search for new cognitive treatments may be aided by 
recognizing apparently similar cognitive dysfunctions in 
what otherwise appear to be very different neuropsychi-
atric phenotypes. In other words, a memory or attentional 
impairment in schizophrenia could possibly be treated with 
a similar medication as in attention deficit-hyperactivity 
disorder (ADHD). This strategy accepts that the enormous 
capacity for comorbidity in psychiatry may also extend to 
the cognitive dimensions. Such considerations mean that the 
treatment of cognitive impairments associated with neuro-
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degenerative diseases that are not generally considered as 
“mental health disorders” may also be germane. Neuro-
degenerative disorders such as Alzheimer disease, Lewy 
body disease, and frontotemporal dementia have deficits 
in major, although somewhat distinct, 
areas of cognition as their defining 
characteristics, although they are not 
usually defined as mental health disor-
ders. Parkinson disease and Huntington 
disease, although classically categorized 
as movement disorders, of course show 
clinically significant impairments in the 
domains of affect and cognition. It can 
hardly be claimed that pharmacological 
treatment of cognitive disorders in these 
conditions has also yet been crowned 
with success, but this experience may 
also prove to be informative. In this 
review, I will focus initially on the status 
of well-established pharmacological 
treatments for cognitive impairments in 
ADHD before considering the present, 
less clear, status of treatment for cogni-
tive deficits in schizophrenia and depression. I will also 
be considering some future prospects for treating cogni-
tion with pharmacological agents in these disorders. Table 
I provides a “roadmap” for this brief survey, indicating 
the main drugs used for treating cognition in these three 
psychiatric disorders (only a few of which are licensed), 
and incidentally illustrating the diversity and wide range of 
mechanisms of these compounds.
Attention deficit-hyperactivity disorder
ADHD in either juveniles or adults is generally thought to 
exemplify so-called “executive” deficits in cognition, which 
comprise such components as working 
memory and planning, cognitive control 
(including inhibitory response control 
and cognitive flexibility)—although 
some authors consider that the impair-
ments extend to broader domains such 
as other aspects of memory.1 Classi-
cally, ADHD also presents with major 
impairments of sustained attention and 
distractibility, which have been demon-
strated to be related to loss of prefrontal 
gray matter, not only in individuals with 
ADHD, but also in their first-degree 
relatives, suggesting a neurobehavioral 
endophenotype of the disorder.2 ADHD is 
generally considered to be one of the few 
success stories in treatment in psychiatry. 
The more severe forms of this disorder 
are generally treated, apparently para-
doxically, with stimulant drugs such as methylphenidate 
or d-amphetamine, which boost catecholamine function 
(ie, dopamine [DA] and noradrenaline [NA]) partially as a 
consequence of their blockade of the DA and NA transporters. 
Other nonstimulant drugs affecting primarily noradrenergic 
function are also employed; such as atomoxetine and guanfa-
cine. Meta-analyses indicate that the stimulants exert respect-
able (medium to large) effect sizes on reducing symptoms 
Many psychiatric  
disorders such as  
autism exhibit  
impairments in social  
cognition that are core  
to the disorder and  
may require novel  
neurobiological  
initiatives and  
methodological  
approaches
ADHD SCHIZOPHRENIA DEPRESSION
Methylphenidate D-cycloserine Vortioxetine
Amphetamine AMPA-R agonists Modafinil
Atomoxetine Memantine
Guanfacine Donepezil
Bupropion Alpha7 nicotinic agonists
Modafinil Amphetamine
Modafinil
Table I. Drugs used in the treatment of cognitive dysfunction in three psychiatric disorders. ADHD, attention deficit- 
hyperactivity disorder; AMPA-R, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor. 
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in both juvenile3 and adult4 ADHD. Nonstimulants such as 
atomoxetine, bupropion, and guanfacine are also effective, 
although with relatively smaller effect sizes. Some analyses 
suggest that amphetamine is also more effective than meth-
ylphenidate, perhaps because of its DA-releasing action.5 A 
large recent meta-analysis6 based on teachers’ and clinicians’ 
ratings as the main outcome measures largely confirmed the 
earlier results, the main recommendation being to employ 
methylphenidate in children with ADHD and amphetamine 
in adult ADHD. These impressive effects are mitigated to 
some extent by tolerability and side effects of these drugs and 
the (presently largely unsupported) fear of possible stimulant 
drug-use disorder. 
However, there is also some evidence that long-term treatment 
with stimulants can have a protective effect against the devel-
opment of psychiatric disorders such as depression, disruptive 
behavior, or anxiety, and there was less likelihood of repeating 
the same school grade.7 Such effects would suggest some 
improvement in academic performance following stimulant 
medication, however, this is controversial. In a controlled 
study, Elia et al8 found that both d-amphetamine and methyl-
phenidate allowed adolescents with ADHD to attempt more 
mathematics and reading tasks, although only d-amphetamine 
improved accuracy of solving maths problems. On the other 
hand, Loe and Feldman9 did not find convincing evidence of 
improved academic outcomes such as reading ability after 
long-term treatment in juvenile ADHD. Arnold et al10 have 
conducted a more recent meta-analysis of effects of treat-
ment using 176 studies of achievement tests (for informa-
tion learned) and academic performance in juvenile ADHD. 
Improvement was found to be more prevalent on achieve-
ment tests than on academic performance per se for juvenile 
ADHD following stimulant drug medication, although the best 
effects were shown with multimodal treatment, also including 
nonpharmacological approaches. 
In parallel to these promising effects on behavioral and 
cognitive outcomes, Nakao et al11 reported from another 
meta-analysis the remarkable result that long-term stimulant 
medication appeared to be associated with a normalization 
of the reduced gray matter volume of basal ganglia struc-
tures commonly found in ADHD - possibly eliminating the 
“developmental delay” often postulated in this disorder. 
These clinical findings on cognition are in general consistent 
with considerable evidence that these drugs improve perfor-
mance on laboratory tests of working memory, sustained 
attention, and inhibitory response control (thus ameliorating 
impulsivity) in both juveniles and adults with ADHD.12 
On the other hand, it has also been reported that although, 
for example, decision-making cognition may be rendered 
less “risky” by methylphenidate, the drug may also fail to 
improve adjustment of risk in the face of changing contin-
gencies.13 This makes it clear that the concept of a general 
“cognitive enhancer” may be inappropriate; cognitive 
benefits may also be accompanied by cognitive costs. This 
consideration is also relevant to the well-known inverted 
U-shaped function that often determines effects of drugs 
on cognition—in its simplest form that optimal effects may 
be obtained by intermediate dose. However, it may also 
be the case that different behavioral and cognitive tasks 
require different doses for optimal effects. Evidence for this 
comes from studies of the effects of L-Dopa on cognition 
in Parkinson’s disease; functions such as spatial working 
memory and cognitive flexibility may be improved but at 
the cost of risky decision making and impaired reversal.14,15 
For ADHD, Sprague and Sleator16 showed that a family 
of inverted U-shaped functions may explain why doses 
producing optimal objectively measured behavioral effects 
of stimulants may not necessarily correspond to teachers’ 
or parents’ ratings of efficacy.
A major concern is that despite the relatively successful use 
of anti-ADHD medications, there is still no definitive under-
standing of how they produce their cognitive enhancing 
effects.17 Although the molecular actions of stimulant drugs 
are quite well understood (eg, their actions on the catechol-
amine transporters), it is still not known, for example, which 
of the two catecholamine neurotransmitters, DA or NA (or 
both in combination) is responsible for their therapeutic 
actions, or where in the brain, for example, in the prefrontal 
cortex or striatum they most effectively operate. Research 
findings in both experimental animals and humans indicate 
that both DA and NA may play a role in executive functions, 
such as working memory, response inhibition, and different 
aspects of attention in the case of DA potentially at either 
prefrontal or striatal DA receptors and for NA especially, 
though not exclusively, in the prefrontal cortex.18 However, 
there are suggestions from some predominantly preclinical 
studies that NA may be more implicated in the control of 
impulsive behavior19,20 and selective attention21,22 whereas 
DA plays important roles in working memory and sustained 
attention.23-25
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Precisely how these neurotransmitter modulations serve 
to improve cognitive performance may depend on their 
ability to enhance information processing by various actions 
on signal-to-noise processing in the prefrontal cortex.18 
However, it is intriguing to consider the possibilities that 
these mechanisms may reflect processes of elevated arousal 
or even reward-related motivational effects; that the cogni-
tive enhancing effects result from interactions between such 
processes and information processing. Stimulant drugs 
are widely known to combat fatigue and drowsiness, but 
the proposal here is that these modulations of arousal can 
directly affect cognition even in the non-sleep-deprived 
subject. 
These research findings and hypotheses have not in general 
yet been tested or translated to human patients with ADHD. 
Another complication is that many of the cognitive bene-
fits observed in ADHD have also been shown in laboratory 
studies of healthy individuals.26,27 This raises an important 
issue; whether the drugs are acting to restore a neurochem-
ical deficit associated with the disorder, or whether they 
are simply producing their cognitive enhancing effects by 
interacting with largely intact systems to compensate for 
dysfunctioning neural networks, caused for example by gray 
matter loss or deficits in functional connectivity. 
Although stimulant drug medication for ADHD has been 
a qualified success, there is still considerable interest in 
the search for superior drugs without the possible stigma 
of being drugs of abuse (although fears of possible stim-
ulant drug dependence in ADHD individuals appear to be 
largely groundless). The atypical stimulant modafinil has 
been considered in this context,27,28 as it is not thought to 
have drug abuse liability but retains many of the cognitive 
benefits of drugs such as methylphenidate. Its neurochem-
ical action is complex; whilst it acts as a weak blocker of 
catecholamine transporters, it has several other actions 
that distinguish it from typical stimulant drugs, including 
possible indirect actions on glutamate and acetylcholine.28,29 
However, modafinil has not been licensed to date for ADHD 
medication and it is not thought be as clinically effective as 
the classical stimulants.6 
Schizophrenia 
It has only been relatively recently accepted that schizo-
phrenia can be associated with profound cognitive deficits, 
for example, in executive function and memory, which are 
a barrier to effective rehabilitation even if the psychotic 
symptoms are controlled. This is a little surprising as it can 
perhaps be argued that virtually the entire expression of 
schizophrenia, including the positive symptoms such as 
delusions and hallucinations, can be thought of as cogni-
tive in nature, albeit in the case of negative symptoms, as 
an interaction between motivational and cognitive mecha-
nisms. Only the positive symptoms are effectively treated, 
with both typical, “first-generation” antipsychotics which 
block DA D2 receptors (-R) and atypical (“second-genera-
tion”) antipsychotics which additionally block 5-HT2A-R, 
amongst others. The psychological mechanisms of these 
antipsychotic effects are largely unknown but may work 
again to affect information processing in the striatum and 
neocortex. There is clearly a potential indirect benefit to 
be had on general cognitive processing if the disruptive 
positive symptoms are blunted, but it is in fact controver-
sial whether there is any residual cognitive benefit, indirect 
or direct. Indeed, there is evidence from studies, both of 
nonhuman primates30 and humans31,32 that chronic treatment 
with so-called “first-generation” antipsychotics acting as 
D2-R antagonists may eventually impair normal cognition. 
The CATIE trial33 failed to find any advantage of the 
“second-generation” agents such as risperidone, quetiapine, 
and olanzapine compared with a typical antipsychotic agent 
perphenazine, although most of the drugs produced small 
but significant improvements in a composite cognitive 
measure. The recent study by Veselinovic et al32 similarly 
showed small-to-moderate effect size improvements in some 
cognitive tests following treatment with second-generation 
agents aripiprazole, olanzapine, and quetiapine. Whether 
these improvements (over baseline and when compared with 
first-generation drugs) are direct effects on cognitive func-
tion is perhaps more questionable. It is possible for example 
that the first-generation drugs, as part of their detrimental 
effects on cognition, also impair practice effects, unlike the 
second-generation drugs which have fewer adverse effects 
and produce a greater sense of well-being. Furthermore, not 
all studies have found a superiority of second-generation 
over first-generation compounds. A large study of effects on 
computerized reversal learning and attentional set-shifting 
found that those first-episode patients treated with atypical 
neuroleptics such as olanzapine and risperidone actually did 
worse than patients on typical antipsychotic medication, in 
well-matched groups.34 
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Medications specifically targeting cognitive deficits and 
usually added to antipsychotic treatment have not been 
very effective on the whole. A recent meta-analysis by 
Sinkeviciute et al35 of 93 trials involving 5630 patients 
categorized cognitive enhancing effects in terms of the 
principal neurotransmitter affected. The most effective 
treatments were glutamatergic, especially α-amino-3-hy-
droxy-5-methyl-4-isoxazolepropionic acid receptor 
(AMPA-R) agonists for working memory, which had a 
small positive effect. Agents acting at the glycine site of 
the NMDA receptor such as D-cycloserine and the gluta-
matergic receptor antagonist memantine showed some 
signs of improvement that were not significant, perhaps as 
a consequence of insufficient statistical power. The precise 
mechanism by which memantine achieves its effects is 
also unclear. It may appear paradoxical that drugs acting 
as glutamate receptor agonists or antagonists may both 
have utility in the treatment of schizophrenia. However, 
NMDA receptor antagonists can enhance glutamate release 
in the cortex and some metabotropic glutamate receptor 
agonists such as the mGluR2/3-R agonist pomaglutemad 
may normalize high levels of glutamate release via their 
actions at presynaptic receptors.36 This action is poten-
tially significant as, following a meta-analysis of several 
clinical trials, this drug was shown to ameliorate positive 
symptoms in schizophrenia only within 3 years of the first 
psychotic episode.37 This may be consistent with theories 
that in the early phases of schizophrenia there is height-
ened activity of cortical pyramidal glutamatergic neurons, 
which may subsequently subside.36 Pomaglutemad has 
not yet been tested for its cognitive enhancing effects in 
schizophrenia, but this finding would suggest that any 
possible cognitive enhancing effects would be limited to 
first-episode patients.
The possible utility of glutamatergic compounds is inter-
esting in view of some evidence that “nootropic” cogni-
tive enhancing compounds such as aniracetam have been 
shown to have possible positive allosteric modulating 
activity at AMPA-R (ie, act as “AMPA-kines”).38 Early signs 
of promise of this class of drug in the treatment of mild 
dementia39 have not led to its wholesale use for Alzheimer 
disease. However, there is some recent evidence that anirac-
etam treatment was superior to cholinesterase inhibition in 
a study of 276 patients with “mild dementia.”40 Moreover, 
an early study showed convincing antagonism of cogni-
tive deficits produced by the cholinergic receptor antag-
onist scopolamine in healthy volunteers.41 Perhaps novel 
nootropic agents which overcome some of the problems 
associated with aniracetam in terms of bioavailability and 
pharmacokinetic factors will be worth trying in schizo-
phrenia as an adjunctive treatment to antipsychotic medi-
cation.
Cholinergic strategies for schizophrenia run somewhat 
parallel to those used in the treatment of Alzheimer disease 
and dementia in Parkinson disease which appear to work 
mainly on attentional function.42,43 Cholinergic strategies 
for schizophrenia have utilised cholinesterase inhibitors 
such as donepezil and alpha7 nicotinic receptor agonists, 
with findings of very small positive effect sizes in both 
cases. For example, Haig et al44 found a small improve-
ment in nonsmoking patients with schizophrenia in verbal 
learning, working memory, and attention. On the other hand, 
a follow-up study by the same group did not confirm these 
findings.45
Sinkeviciute et al35 found no evidence for efficacy of agents 
affecting serotonergic, noradrenergic, and γ-aminobutyric 
acid (GABA)-ergic receptors. However, they pointed out 
a glaring gap in the use of dopaminergic agents. This may 
appear to be surprising in view of the therapeutic use of 
DA D2-R antagonists, but there is substantial preclinical 
evidence that D1-R agonists may enhance working memory 
function in the primate prefrontal cortex,23 as well as atten-
tion in rodent studies,24 which has never been adequately 
tested clinically. This has been due to existing compounds 
having poor brain penetration, short half-lives, and also 
some adverse cardiovascular effects. However, the advent 
of a new class of D1-R agonists with positive allosteric 
modulation (PAM) may be worth pursuing in an appropriate 
clinical trial. 
In the current absence of a clinically viable D1-R agonist, 
other less specific agents, such as those used for ADHD, 
may also be worth further scrutiny. A considerable compli-
cation is the possible induction of psychosis by psycho-
motor stimulants such as amphetamine. However, it is 
possible that dopaminergic agents such as methylpheni-
date or modafinil may have some efficacy if investigated 
in large-scale trials in suitable groups of patients. In 
support of this hypothesis, Daniel et al46 found in an fMRI 
study of a small sample of patients with schizophrenia 
that d-amphetamine enhanced blood flow in the dorsolat-
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eral prefrontal cortex and improved performance on the 
Wisconsin Card Sorting Test. Likewise, Barch and Carter47 
found benefit in several aspects of cognition including 
spatial working memory, language production, Stroop 
performance, and reaction time in 10 patients receiving 
d-amphetamine in addition to haloperidol medication. The 
rationale is that the D1-R action will be unaffected by 
the antipsychotic D2-R medication which may also block 
the psychotic effects of the drug. Turner et al48 showed 
that modafinil, which has mild catecholaminergic and 
possible glutamate-enhancing function,29 also improved 
performance in high functioning, first episode patients 
performing some CANTAB tests of fronto-executive func-
tion including attentional-set shifting, recognition memory, 
planning, and response inhibition. However, longer-term 
treatment with either modafinil (or armodafinil) has so far 
failed to show significant effects.35 Nevertheless, a recent 
study49 found that the cognitive enhancing effects of acute 
modafinil in schizophrenia depended to some extent on the 
sensitivity of the cognitive test battery used, the CANTAB 
tests being more sensitive than the commonly used 
MATRICS battery. In general, factors such as this, as well 
as optimal dosing and the choice of suitable subgroups of 
patients with schizophrenia, given its heterogeneity, may 
be necessary to adequately test the efficacy of cognitive 
enhancers in schizophrenia. 
Depression
Some of the major symptoms of depression such as 
impairments in concentration and decision-making have 
an obvious cognitive nature. However, these are often 
overlooked because of the clinician’s emphasis on mood 
disorder. Indeed, cognitive dysfunction in depression has 
attracted considerable controversy because of the obvious 
interpretative problem, also relevant in terms of the “nega-
tive” symptoms of schizophrenia, of motivational or mood 
factors in depression that may indirectly influence cogni-
tion. It has also been suggested that some of the cognitive 
difficulties in depression may have resulted from disruptive 
effects of enhanced responses to negative feedback.50 This 
motivational-cognitive interaction may thus be particularly 
important in depression. Nevertheless, it is now gener-
ally accepted that there are neurocognitive impairments 
in depression that are associated with poorer functional 
outcome and increased probability of relapse—and which 
importantly are not completely remediated by current 
treatments for depression such as antidepressant medica-
tion. A recent meta-analysis51 showed a modest positive 
effect on functions such as divided attention, executive 
function, immediate memory, processing speed, recent 
memory, and sustained attention (though not working 
memory) for depressed participants. However, this effect 
was largely limited to the selective serotonin reuptake inhib-
itors (SSRIs) rather than tricyclic antidepressants (perhaps 
because of their additional anticholinergic actions). The 
precise mechanisms underlying these cognitive enhancing 
effects of SSRIs is unknown. Chronic SSRIs, in addition to 
producing adaptive changes in serotonergic function may 
also affect other neurotransmitter systems (eg, DA), and 
affect neurogenesis in the hippocampus. Prado et al51 do not 
rule out the possibility that the effects are indirect effects 
of mood enhancement. This relative lack of efficacy means 
that impairments are often still evident in remitted depressed 
patients. Hence cognition has recently become an important 
target for treatment in depression. 
With this aim in view, McIntyre et al52 have reported cogni-
tive enhancing actions in depression of 8 weeks of treat-
ment with a novel SSRI antidepressant, vortioxetine on a 
composite cognition end point comprising the Rey Audito-
ry-Verbal Learning Test and the Digit-Symbol Substitution 
Test from the Wechsler Adult Intelligence Scale, together 
with a number of other secondary cognitive test outcomes. 
Importantly, mediation analyses showed that this cognitive 
enhancing effect was not associated with its mood-elevating 
effects, suggesting the possibility of parallel effects on mood 
and cognition, via serotoninergic actions. Vortioxetine is an 
SSRI with additional actions at 5-HT3, and 5-HT7 recep-
tors but it is not yet clear whether and how these contribute 
to cognitive enhancing effects. One suggestion has been 
that its 5-HT3 action may serve to disinhibit GABA-ergic 
receptors on interneurons.53 Further mechanistic studies are 
indicated in healthy volunteers and in studies with experi-
mental animals. 
It may also be feasible to augment treatment of depres-
sion with SSRIs by other drugs that have greater cognitive 
enhancing efficacy. Goss et al54 found in another meta-anal-
ysis that modafinil produced added benefit for cognition 
when combined with standard antidepressant medica-
tion. Kaser et al55 showed that modafinil did indeed act to 
improve working memory and episodic memory, but not 
planning or attention in remitted depressed patients. 
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Conclusions
There are indications of gradual progress in understanding 
and treating cognitive deficits in psychiatric disorders, but 
it is clear that there is much to be accomplished, in terms 
not only of identifying valid targets but also in the meth-
odology for assessing their effects in clinical trials and in 
experimental medicine studies. A likely area of advance 
is in methods of evaluating social cognition and related 
forms, where emotional processing interacts with cogni-
tion (so-called “hot”cognition). For example, many psychi-
atric disorders such as autism exhibit impairments in social 
cognition that are core to the disorder and may require 
novel neurobiological initiatives and methodological 
approaches, in addition to clinical trials. Attempts to reme-
diate social cognition in autism via intranasal oxytocin 
represents one such promising direction.56 Overall, this 
review has argued that more studies are required to define 
the mechanistic bases of cognitive enhancement produced 
by both currently employed and yet-to-be discovered phar-
macological agents. n
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